|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that NGF metabolic dysfunction contributes to sevoflurane-associated BFCNs degeneration and subsequent cognitive deficits.
|
30481505 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
The NGF pathway may also have potential as a biomarker of cognitive decline in AD, as its changes can predict future cognitive decline in patients with Down syndrome as they develop preclinical Alzheimer's pathology.
|
30809111 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
The cross-talk between NGF and insulin pathways downstream the insulin receptor suggests novel potential therapeutic targets to slow cognitive decline in AD and diabetes-related brain insulin resistance.
|
29736736 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Low-Molecular-Weight NGF Mimetic Corrects the Cognitive Deficit and Depression-like Behavior in Experimental Diabetes.
|
28740732 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
According to much research, neurodegeneration and cognitive decline in Alzheimer disease (AD) are correlated with alternations of neurotrophic factors such as nerve growth factor, brain-derived neurotrophic factor, and glial cell-derived neurotrophic factor.
|
29114922 |
2018 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
To determine whether stereotactically guided intracerebral injections of adeno-associated viral vector (serotype 2)-nerve growth factor (AAV2-NGF) are well tolerated and exhibit preliminary evidence of impact on cognitive decline in mild to moderate AD-associated dementia.
|
29582053 |
2018 |
|
Impaired cognition
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A missense mutation (R100W) in the beta-NGF gene was found in hereditary sensory autonomic neuropathy V (HSAN V) patients with severe loss of pain perception but without overt cognitive impairment.
|
30524266 |
2018 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we studied the effect of amyloid beta-peptides (Aβ), interleukin 1-beta (IL-1β), and CSF from AD, Lewy body dementia (LBD) or subjective cognitive impairment (SCI) patients on the NGF overproducing cell line NGC-0295.
|
30092220 |
2018 |
|
Impaired cognition
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ALA enhanced NGF levels in hippocampus and cortex and prevented cognitive impairment.
|
28606823 |
2017 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neurotrophic factors, such as nerve growth factor (NGF), can prevent neuronal damage and rescue the cholinergic neurons that undergo cell death in AD, reverse deposition of extracellular amyloid plaques and improve cognitive deficits.
|
28351757 |
2017 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, our results suggest that HJG possesses neurotrophic effects similar to those of NGF, and can ameliorate cognitive dysfunction in a rat dementia model via CREB activation.
|
29209220 |
2017 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Alterations in the expression and signaling of brain-derived neurotrophic factor (BDNF) and the precursor to nerve growth factor (NGF), proNGF, play a role in the neuronal and cognitive dysfunction of Alzheimer's disease.
|
24112788 |
2014 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
To test whether encapsulation of this cell line provides a relevant dose escalation step in delivering NGF for treatment of the cognitive decline in AD patients, we have validated the bioactivity of devices with NGC0211 and NGC-0295 cells in normal rat striatum as well as in the quinolinic acid striatal lesion model.
|
22113314 |
2012 |
|
Impaired cognition
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To address the clinical neurocognitive roles of nerve growth factor (NGF) genetic polymorphism in early-stage Alzheimer's disease (AD) and amnestic mild cognitive impairment (A-MCI), we investigated the association between this single-nucleotide polymorphism (SNP) and executive dysfunction as a nonmemory cognitive impairment.
|
22301435 |
2011 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
The therapeutic potential of using human NGF to provide a long-lasting cholinergic trophic support, thereby preventing or slowing cognitive decline in AD patients, has therefore a strong rationale.
|
19355851 |
2009 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
A NGF gene therapy trial reduced cognitive decline and stimulated cholinergic fiber growth in humans with mild AD.
|
18986241 |
2008 |
|
Impaired cognition
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results of this investigation demonstrate that long-term increases in dopamine D(2) receptor sensitivity produce significant decreases in hippocampal cholinergic and NGF expression that may result in cognitive impairment.
|
15066159 |
2004 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, transplantation of NT2N neurons genetically modified to express nerve growth factor significantly attenuated cognitive dysfunction following traumatic brain injury in mice.
|
12722829 |
2003 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results show that naturally occurring age-related memory loss can be reversed by grafting cells engineered to secrete NGF directly to the NBM, and that either cholinergic hyper- or hypofunction may lead to cognitive impairments.
|
7722631 |
1995 |